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Abstract
Heterotopic ossification (HO) is the pathological formation of
ectopic endochondral bone within soft tissues. HO occurs following
mechanical trauma, burns, or congenitally in patients suffering
from fibrodysplasia ossificans progressiva (FOP). FOP patients carry
a conserved mutation in ACVR1 that becomes neomorphic for
activin A responses. Here, we demonstrate the efficacy of BYL719,
a PI3Ka inhibitor, in preventing HO in mice. We found that PI3Ka
inhibitors reduce SMAD, AKT, and mTOR/S6K activities. Inhibition
of PI3Ka also impairs skeletogenic responsiveness to BMPs and the
acquired response to activin A of the Acvr1R206H allele. Further, the
efficacy of PI3Ka inhibitors was evaluated in transgenic mice
expressing Acvr1Q207D. Mice treated daily or intermittently with
BYL719 did not show ectopic bone or cartilage formation. Further-
more, the intermittent treatment with BYL719 was not associated
with any substantial side effects. Therefore, this work provides
evidence supporting PI3Ka inhibition as a therapeutic strategy for
HO.
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Introduction
Heterotopic ossification (HO) is a pathology characterized by ectopic
bone formation in soft tissues at extraskeletal sites. Trauma-induced
HO develops as a common post-operative complication after ortho-
pedic surgeries (e.g., hip arthroplasty), blast injuries, skeletal
trauma, deep burns, and nervous system injuries. Clinical therapy is
now limited to anti-inflammatory drugs, radiation, or surgical exci-
sion of the already formed bone, which is associated with a higher
recurrence rate (Dey et al, 2017; Eisenstein et al, 2017). In addition
to trauma-induced HO, fibrodysplasia ossificans progressiva (FOP)
is a devastating congenital autosomal dominant disorder also
involving HO (Bravenboer et al, 2015). Ectopic bones form progres-
sively through endochondral ossification, mostly in episodic flare-
ups associated with trauma and inflammation. Cumulative effects of
these osteogenic events include progressive immobility resulting
from ankylosing joints. Individuals affected have a shorter life span,
most commonly due to thoracic insufficiency syndrome (Kaplan
et al, 2010; Pignolo et al, 2016).
The genetic cause of FOP arises from gain-of-function mutations
in the bone morphogenetic protein (BMP) type I receptor ACVR1
(Shore et al, 2006). Several reports demonstrated that ACVR1 muta-
tions in FOP are neomorphic, abnormally transducing BMP signals
in response to activin A (Hatsell et al, 2015; Hino et al, 2015).
Therefore, whereas activin A normally transduces a pSMAD2/3
signal through the ACVR2-ACVR1B complex, it forms a non-
signaling complex with ACVR2 and wild-type ACVR1. However, the
neomorphic ACVR1 allele in FOP elicits SMAD1/5 phosphorylation
upon activin A binding to the ACVR2-ACVR1R206H receptor complex
(Hatsell et al, 2015; Hino et al, 2015). In contrast to FOP, which
results from improper activation of FOP-mutant ACVR1 by activin
A, non-genetically driven HO appears to arise from excessive BMP
signaling with functional redundancy between different BMP type I
receptors (Agarwal et al, 2017).
Trauma-induced HO and FOP are initiated by local connective
tissue destruction, and require inflammation (Pignolo et al, 2013;
Convente et al, 2018). This inflammatory microenvironment acti-
vates a resident pool of interstitial progenitors that aberrantly
undergo chondrogenesis and further ectopic bone formation (Dey
et al, 2016; Lees-Shepard et al, 2018). BMP signaling plays a major
inductive role in HO progression: chondrogenesis and osteoblast
specification and maturation (Salazar et al, 2016). Therefore, target-
ing BMP signaling in all these cell types and pathogenic steps would
be required for efficient therapeutic treatments.
Genetic and pharmacological studies indicated that chondroblast
and osteoblast specification and maturation depend on phos-
phatidylinositol 3-kinase (PI3K; Fujita et al, 2004; Ford-Hutchinson
et al, 2007; Ikegami et al, 2011). We have previously demonstrated
that PI3Ka is critical for bone formation through regulation of
SMAD1 degradation and activity (Ga´mez et al, 2016). The PI3K-
AKT axis also integrates additional major osteogenic signaling
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pathways (e.g., mTOR, FOXO, or GSK3; Vanhaesebroeck et al,
2010; McGonnell et al, 2012). Recent studies also pointed out the
critical role of mTOR in HO and FOP (Hino et al, 2017; Qureshi
et al, 2017). Hence, we hypothesized that a therapy based on PI3K
inhibitors could be effective because it would target both the chon-
drogenic and osteogenic steps of heterotopic ossification, by target-
ing multiple pathways downstream of PI3K/AKT. Among PI3K
inhibitors, BYL719 is an isoform a-selective inhibitor under investi-
gation in clinical trials of patients with PIK3CA-altered solid tumors
that demonstrated good tolerability (Juric et al, 2018). The data
presented here show the potent therapeutic effect of PI3Ka inhibi-
tion on HO in vivo.
Results
Inhibition of PI3Ka abrogates SMAD1/5 and mTOR/S6K activation
by Acvr1R206H in mesenchymal progenitors
Heterotopic endochondral ossification is driven by a resident pool of
mesenchymal stem cells at sites of tissue inflammation. It has been
shown that fibro/adipogenic precursors (FAPs) are the major cells
of origin of heterotopic ossification in both injury-induced and spon-
taneous HO (Dey et al, 2016; Lees-Shepard et al, 2018). We gener-
ated cultures of mesenchymal stem cells (MSCs) from control mice
and infected them with mock virus or with viruses expressing
moderate levels of wild-type Acvr1 (WT), Acvr1Q207D (QD), or
Acvr1R206H (RH) (Fig 1A and B). In agreement with previous data
(Hatsell et al, 2015), the expression of Acvr1R206H altered the signal-
ing properties of ACVR1 in response to activin A as shown by
SMAD1/5 phosphorylation (Fig EV1A).
Our group have shown that PI3Ka activity increases cellular
levels of SMAD1/5 by reducing its phosphorylation by GSK3 in
osteoblasts (Ga´mez et al, 2016). Addition of A66, a PI3Ka-specific
inhibitor, reduced SMAD1/5 levels in MSCs, decreased GSK3 phos-
phorylation, and reduced BMP responsiveness (Fig EV1B). Further-
more, PI3Ka inhibition strongly decreased the expression of
osteoblast markers (Bglap, Col1a1, Dlx5, and Osx/Sp7) upon osteo-
genic differentiation of MSCs (Fig EV1C). Therefore, we analyzed
the effects of A66 in MSCs transduced with wild-type Acvr1 or
Acvr1R206H. Addition of A66 reduced the phosphorylation of GSK3,
p38, and S6 independently of the transduced Acvr1 allele (Fig 1C).
Similarly, A66 reduced SMAD1 protein levels and SMAD1/5 phos-
phorylation. We also analyzed the effects of PI3Ka inhibition on the
response to BMP6 and the shifted responsiveness of Acvr1R206H
upon activin A addition (Hino et al, 2015; Alessi Wolken et al,
2018). A66 was also able to reduce the levels of pSMAD1/5 upon
BMP6 or activin A stimulation in Acvr1R206H transduced cells
(Fig 1C). These data suggest that PI3Ka inhibition reduces SMAD1/
5, AKT, and mTOR/S6K activity in mesenchymal precursors, and
impairs responsiveness to canonical BMPs and the acquired
response to activin A of Acvr1R206H.
Inhibition of PI3Ka reduces osteochondroprogenitor
differentiation potential induced by Acvr1Q207D or Acvr1R206H
The reduction in the activation of SMAD1/5, p38, and S6K caused
by inhibition of PI3Ka suggested that cell progenitors could have
decreased skeletogenic potential. To test this hypothesis, we trans-
duced MSCs with wild-type Acvr1 (WT), Acvr1Q207D (QD), or
Acvr1R206H (RH), and treated them with BMP2, BMP6, or activin A.
Expression of the SMAD1/5-dependent gene Id1 indicated its known
sensitivity to either BMP2 or BMP6 (Fig 2, upper panels). More
importantly, activin A addition confirms previous observations that
the TGFb/activin A signal through SMAD2/3 inhibits Id1 expression
from endogenous receptors (Lee et al, 2005). However, the expres-
sion of mutant ACVR1 shifted responsiveness to enhanced Id1 tran-
scription by activin A. In all conditions, addition of the PI3Ka
inhibitor led to a marked decrease in the activation of Id1 gene
expression induced by BMP2, BMP6, or activin A. We also analyzed
the expression of chondrocyte and osteoblast markers in these
experimental conditions. The PI3Ka inhibitor reduced the expres-
sion levels of Sox9, a chondrocyte marker, by about 50% and also
diminished its induction upon BMP2 addition (Fig 2). Transduction
of Acvr1-mutant forms also led to increased expression and higher
sensitivity to BMP2 and activin A of Dlx5, an early osteoblast
marker (Acampora et al, 1999), Osx/Sp7, a osteochondroprogenitor
marker (Nakashima et al, 2002; Fig 2, lower panels), and increased
expression and higher sensitivity to BMP2 of Bglap, a osteoblast
marker (Fig EV2). Again, the addition of A66 almost abolished these
inductive effects of Acvr1R206H or Acvr1Q207D on Dlx5, Bglap, and
Osx expression (Figs 2 and EV2). Altogether, these results demon-
strate the ability of PI3Ka inhibitors to reduce the specification of
mesenchymal progenitors into skeletal lineages.
Inhibition of PI3Ka blocks heterotopic ossification in
Acvr1Q207D mice
To further explore the ability of PI3Ka inhibitors to abrogate HO
in vivo, we took advantage of transgenic mice expressing the consti-
tutively active allele ACVR1Q207D (CAG-Z-EGFP-ACVR1Q207D;
Fukuda et al, 2006). Since ACVR1Q207Dfl/fl mice injected with cardio-
toxin and CRE-expressing adenovirus develop robust local HO, this
mouse model has been used extensively to search inhibitors of HO
(Yu et al, 2008; Shimono et al, 2011; Agarwal et al, 2016). Although
A66 potently inhibits PI3Ka in vitro (IC50 32 nM), its short half-life
in plasma impeded its further clinical development. Structural modi-
fications based on A66 resulted in BYL719 (alpelisib), which
possesses optimal PI3Ka selectivity and potency (IC50 4.6 nM), with
better pharmacokinetic properties in mice and humans (Fritsch
et al, 2014; Juric et al, 2018; Venot et al, 2018). BYL719, which is
orally bioavailable, demonstrated a good safety profile in humans,
and has been shown to be clinically effective in patients with
PIK3CA-related overgrowth syndrome (PROS) and patients with
PIK3CA-altered solid tumors (Juric et al, 2018; Venot et al, 2018).
We confirmed that BYL719 also reduced SMAD1/5, AKT, and
mTORC1 signaling in MSCs (Fig EV3A). BYL719 was also able to
reduce the levels of SMAD1 levels and its phosphorylation upon
BMP6 or activin A stimulation in Acvr1R206H transduced cells
(Fig EV3B) and decrease the expression of osteoblast markers
(Bglap, Col1a1, Dlx5, Osx/Sp7, and Runx2) upon osteogenic dif-
ferentiation of MSCs (Fig EV3C).
Preclinical oncological studies with PI3Ka inhibitors suggest that
intermittent administration might allow higher dosing than continu-
ous treatment, with similar efficacy and lower undesired effects
(Fruman et al, 2017). Furthermore, preclinical studies in mice
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indicate that a daily dose of 25–30 mg/kg allows tumor regression
and AKT inhibition in tumors, without leading to hyperglycemia
and hyperinsulinemia (Fritsch et al, 2014). In order to study which
regime would be safer and more effective in HO, we investigated
two dosing strategies: daily doses of 25 mg/kg of BYL719 and inter-
mittent doses of 25 mg/kg starting 24 h after intramuscular injec-
tion of cardiotoxin and CRE adenovirus (Fig 3A). Vehicle-treated
ACVR1Q207D mice developed HO in the injected site by P30 with a
high penetrance (13 out of 16 mice; Fig 3B). lCT analysis showed
that heterotopic bony tissues were typically embedded in muscle
and soft tissues, although apposition to limb skeletal elements was
also observed (Fig 3C, Movies EV1–EV3). On the contrary, daily or
intermittent administration of BYL719 prevented heterotopic bone
formation, and only one animal of each group showed minimal
bone formation compared with vehicle-treated mice (Fig 3B–D).
Histological evaluation by H&E, Masson’s trichrome, and fast
green/safranin O (FGSO) staining revealed that extraskeletal bone
lesions contain cartilage, marrow, and bone structures, suggesting
an active process of endochondral ossification (Figs 4A and B, and
EV4A). Daily or intermittent BYL719-treated mice did not show
major bone or cartilage formation in the injected hindlimb at P30
(Figs 4A and B, and EV4). Moreover, H&E staining demonstrated
the absence of mesenchymal condensations and fibroproliferative
processes, but instead a completed repair of injured skeletal muscle
in BYL719-treated ACVR1Q207D mice (Fig 4B). Altogether, these
results suggest that PI3Ka inhibition was effective at suppressing
HO in a mouse model, even at their earlier stages.
A drawback of PI3Ka-selective inhibitors is their inevitable, on-
target adverse effects on glucose metabolism, as PI3Ka is the main
isoform mediating this function (Sopasakis et al, 2010; Smith et al,
A
C
B
Figure 1. PI3Ka inhibition reduces SMAD1/5, AKT, and mTOR/S6K activity in MSCs.
A, B mRNA and protein levels of MSCs infected with mock virus or with viruses expressing wild-type Acvr1 (WT), Acvr1Q207D (QD), or Acvr1R206H (RH). Data shown as
mean  SEM (n = 4 per group). ***P < 0.001; one-way ANOVA.
C Immunoblots of MSCs expressing wild-type Acvr1 (WT) or Acvr1R206H (RH) variants. MSCs were serum-starved and treated with 10 lM A66 (PI3Ka inhibitor) for 16 h
and then treated with 2 nM BMP6 or 2 nM activin A for 1 h.
Source data are available online for this figure.
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2012). In addition, p110a is the most abundant class IA isoform in
bone tissues, and we previously demonstrated its critical role in
bone development (Ga´mez et al, 2016). Therefore, we focused on
the effects of BYL719 treatment in metabolic and bone parameters.
Although daily dosing of BYL719 led to a significant decrease in
body weight of treated animals, intermittent dosage did not decrease
Figure 2. PI3Ka inhibition reduces the specification of cell progenitors into chondrogenic and osteogenic lineages.
mRNA expression of osteoblast and chondroblast-specific genes of MSCs expressing wild-type Acvr1, Acvr1R206H, or Acvr1Q207D.MSCs were serum-starved and treated with
10 lM A66 for 16 h and then treated with 2 nM BMP2, 2 nM BMP6, or 2 nM activin A for 2 h. Data shown as mean  SEM (n = 4 per group). *P < 0.05, ** or ##P < 0.01,
*** or ###P < 0.001; two-way ANOVA. Asterisks refer to significance between MSCs treated with or without A66 in each case. Similarly, # refers to significance between
Acvr1R206H or Acvr1Q207D MSCs of each group compared to wild-type Acvr1 in cells untreated with A66.
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their body weight or femur length (Fig 5A and B). Similarly, analy-
sis of cortical parameters around the femoral midshaft revealed
lower bone perimeter and cortical thickness only in animals treated
daily (Fig 5C). These data suggest some effects of daily BYL719
dosage in mice but absent in those mice treated intermittently.
Further analysis of femoral trabecular bone parameters gave similar
results on bone homeostasis: some osteopenic effects of daily dosing
whereas no changes developed in those animals treated intermit-
tently (Fig 5C). Moreover, we found no obvious changes in the
circulating levels of glucose or triglycerides, irrespective of the peri-
odicity of the BYL719 treatment (Fig 5D). Therefore, our data
suggest that BYL719 has a good therapeutic window for the treat-
ment of heterotopic ossifications, which also agrees with clinical
data recently reported in other pathologies (Juric et al, 2017, 2018;
Venot et al, 2018).
Discussion
HO is a pathological process induced by musculoskeletal trauma or
a congenital gain-of-function mutation of the ACVR1 gene. In both
cases, these events converge in an abnormal SMAD1/5 signaling,
since inhibition of BMP receptor activity reduces bone formation in
HO and FOP mouse models (Yu et al, 2008; Agarwal et al, 2017).
We have identified that PI3Ka inhibitors (A66 or BYL719) block
several BMP-activated signaling pathways. Moreover, we have
shown that BYL719 treatment rescues the HO phenotype in a mouse
model with a promising safety profile. There are several advantages
for implementing BYL719 as a therapeutic candidate for HO and
FOP: First, inhibition of PI3Ka in mesenchymal progenitors
suppresses at least two signaling pathways required for progression
of HO downstream of BMP receptors, SMAD1 and mTOR. Mechanis-
tically, we previously showed that PI3Ka inhibitors increased
SMAD1/5 degradation by modulation of GSK3 activity, reducing
transcriptional responsiveness to BMPs. Accordingly, mice deficient
for PI3Ka activity in osteoblasts were osteopenic (Ga´mez et al,
2016). In addition to canonical SMAD1/5, recent reports demon-
strated that activation of mTOR, downstream of PI3K/AKT, is also
critical for FOP and non-genetic HO in preclinical models (Hino
et al, 2017; Qureshi et al, 2017). We propose that targeting PI3Ka/
AKT has the potential to suppress HO by the inhibition of both
pathways.
Whereas ACVR1R206H activity is still ligand-dependent (to either
BMPs or activins), ACVR1Q207D has ligand-independent activity and
induces higher chondrogenesis and ossification in functional assays
and mouse models of HO (Yu et al, 2008; Haupt et al, 2014; Dey
et al, 2016). Our results demonstrated that PI3Ka inhibitors are able
to suppress excessive cellular responses induced by classical BMP
ligands, as well as the neomorphic signaling by activin A.
ACVR1Q207D is a well-accepted model of HO (Yu et al, 2008; Dey
et al, 2016), where the mutant allele can be activated post-natally
and the phenotype can be rescued by PI3Ka inhibition. Available
data indicate some capacity of cells without expression of the
mutated allele to contribute to heterotopic lesions (Chakkalakal
et al, 2012; Dey et al, 2016; Lees-Shepard et al, 2018). Similarly,
non-genetic HO develops in the absence of receptor alterations but
with enhanced SMAD and mTOR activities (Agarwal et al, 2017;
Qureshi et al, 2017). We still do not know the relative contribution
of the therapeutic effects of BYL719 in normal cells in the lesion
environment compared with the effects in mutated cells (expressing
the ACVR1Q207D allele). In any case, both mutated and wild-type
cells within lesions with acquired higher SMAD and mTOR signaling
would be targeted by PI3Ka inhibitors (Chakkalakal et al, 2012).
PI3Ka inhibitors likely target different cell types required for HO
lesion progression. Our data demonstrate that PI3Ka inhibition
reduces chondrocyte and osteoblast commitment of MSCs. During
cartilage development, PI3K is required for chondrocyte differentia-
tion, survival, and hypertrophy (Beier & Loeser, 2010). The expres-
sion of activated AKT in transgenic mice promoted chondrocyte
differentiation, whereas a dominant-negative form delayed this
process (Rokutanda et al, 2009). Furthermore, inactivation of Pten
in cartilage showed skeletal overgrowth and accelerated chondro-
cyte hypertrophy (Ford-Hutchinson et al, 2007; Ikegami et al,
2011). A large body of evidence pointed to PI3Ka function as being
also essential for osteoblast specification, bone development, and
skeletal maintenance (Liu et al, 2007; Guntur & Rosen, 2011;
◀ Figure 3. PI3Ka inhibition suppresses heterotopic ossification in mice.A Scheme of the experimental protocol. Heterotopic ossification was induced at P7 with adenovirus-Cre (Ad.Cre) and cardiotoxin (CTX) injection. Control groups only
received CTX injection. Drug treatments started on P8. Daily BYL719 (25 mg/kg) or DMSO was administered once a day. Intermittent BYL719 groups received only five
(25 mg/kg) BYL719 injections as indicated.
B Summary of experimental results expressed as ratio between mice with heterotopic ossifications on P30 and the total mice per group. No spontaneous or CTX-
induced HO was observed.
C Representative microtomography frontal 3D images of heterotopic ossification groups. White arrows show heterotopic ossifications. Close-up images of each example
show injected left hindlimb.
D Quantification of heterotopic ossifications of each experimental group. Black symbols indicate the absence of HO. Red symbols indicate HO. Data shown are of each
individual mouse with group median. Significance is shown between Acvr1Q207D groups. **P < 0.01, ***P < 0.001, Kruskal–Wallis test with Dunn’s multiple
comparison test.
▸Figure 4. Histological analysis of injected hindlimbs.A Representative images of hematoxylin and eosin (H&E), fast green/safranin O (FGSO), and Masson’s trichrome staining in control and Acvr1Q207D mice. Images were
obtained with stereomicroscope (scale bar = 1,000 lm).
B Close-up representative images of Acvr1Q207D-expressing groups shown in (A). Microscopy images were shown with 2× (scale bar = 1,000 lm) and 4× (scale
bar = 500 lm). For FGSO, cartilage is labeled in orange/red. For Masson’s trichrome, osteoid is labeled in blue and muscle in red.
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Xian et al, 2012; Ga´mez et al, 2016). Similarly, angiogenesis selec-
tively requires PI3Ka to control endothelial cell migration (Graupera
et al, 2008). Tissue inflammation has been strongly associated with
the onset of HO, and depletion of mast cells and macrophages has
been shown to impair HO in FOP mouse models (Shore & Kaplan,
2010; Convente et al, 2018). Since PI3Kc and PI3Kd are the domi-
nant isoforms and the role of PI3Ka is extremely restricted in
immune cells, it is less likely a direct effect of BYL719 on macro-
phage or mast cell function (Fruman et al, 2017). However, we
cannot exclude an indirect effect in the recruitment of inflammatory
cells and the establishment of a permissive tissue microenvironment
for HO progression. Finally, BYL719 demonstrated a good tolerabil-
ity and safety profile in humans and has been shown to be clinically
effective in patients with PIK3CA-related overgrowth syndrome
(PROS) and patients with PIK3CA-altered solid tumors (Juric et al,
2018; Venot et al, 2018). This evidence resulted in its recent
approval by the FDA for the treatment of PIK3CA-mutant advanced
or metastatic breast cancer. Therefore, BYL719 has been well evalu-
ated regarding its pharmacokinetics, administration, tolerated dose,
and side effects in humans and mice (Fritsch et al, 2014; Juric et al,
2018; Venot et al, 2018). Daily oral doses of 400 mg of BYL719 were
well tolerated by patients in a phase Ia study in PIK3CA-altered solid
tumors (Juric et al, 2018), whereas PROS patients, after 18 months,
are still been treated daily with 250 mg of BYL719 without major
complications (Venot et al, 2018). The recommended BYL719 dose
approved by the FDA is 300 mg (two 150 mg film-coated tablets)
taken orally, once daily. In these studies, the most frequent adverse
effect was peripheral insulin resistance and hyperglycemia, an effect
of PI3Ka inhibition that could be managed by concomitant oral
antidiabetic medication (Juric et al, 2018; Venot et al, 2018). In
mice, pharmacokinetic studies showed that a daily dose of BYL719
of 25 mg/kg is sufficient to keep more than 90% of AKT activity
inhibited and to abrogate growth of grafted tumors (Fritsch et al,
2014). These studies also demonstrate a window of therapeutic
opportunity without adverse effects between 10 and 40 mg/kg
(Fritsch et al, 2014). Thus, repurposing BYL719 for the treatment of
HO, at least during a restricted temporal window (i.e., soft tissue
trauma and surgery to remove ectopic bone in HO, or during flare-
ups in FOP patients), should pose few contraindications. Our work
in young mice (from P7 to P30) showed that mice treated daily with
25 mg/kg of BYL719 had normoglycemia but have reduced growth
rate and developed osteopenia over time. However, those treated
with intermittent dosage did not show any detectable adverse effect
while maintaining therapeutic efficacy. Intermittent dosing has been
yielding encouraging data for PI3K inhibitor therapeutic strategies in
humans (Fruman et al, 2017). For instance, intermittent dosing of
PI3Ka inhibitors in clinical trials allowed more pronounced acute
PI3K/mTOR pathway inhibition with fewer adverse effects in
normal tissues (Ma et al, 2016; Juric et al, 2017). Over the last
years, beyond anti-inflammatory drugs, potential treatments for FOP
have been developed and are currently in ongoing clinical trials.
Some treatments focus on ACVR1 activation (e.g., anti-activin A
antibody or ACVR1 kinase inhibitors), while others, such as the
PI3Ka inhibitors presented here, target cells and signaling pathways
required for heterotopic ossification downstream ACVR1 (e.g., palo-
varotene or rapamycin; Wentworth et al, 2019). ACVR1 is almost
ubiquitously expressed, and the pathways targeted by these drugs
are also involved in multiple physiological and developmental
processes. Therefore, in addition to therapeutic efficacy, side effects
in multiple tissues must be carefully monitored. Noteworthy,
BYL719 has demonstrated a good safety profile in children suffering
PROS treated daily for more than a year (Venot et al, 2018).
However, it remains to be investigated whether BYL719 can have
any undesirable effect specifically related to the abnormal SMAD1
signaling downstream ACVR1R206H in FOP patients. In addition,
further studies should be performed to optimize dosing and timing
of administration or to evaluate combinatorial approaches with
other pharmacological agents (i.e., anti-inflammatories).
Materials and Methods
Murine bone marrow mesenchymal stem cell isolation
and culture
Murine bone marrow-derived mesenchymal stem cells (BM-MSCs)
were isolated from 6- to 8-week-old C57BL6/J mice as previously
described (Soleimani & Nadri, 2009). Mice were euthanized, and
femurs were dissected and stored in DMEM (Biological Industries)
with 100 U/ml penicillin/streptomycin (P/S). Under sterile condi-
tions, soft tissues were cleaned and femur ends were cut. Bone
marrow was strongly flushed with media using a 27-gauge needle,
and cell suspension was filtered through a 70-lm cell strainer (BD
Falcon) and seeded in a 100-mm cell culture dish. Non-adherent cells
were discarded after 3 h. Media were slowly replaced every 12 h for
up to 72 h. Then, media were replaced every 2 days until 70% con-
fluence was reached. At this stage, cells were washed with warm
PBS and lifted by incubation with 0.25% trypsin/0.02% EDTA for
5 min at room temperature. Lifted cells were cultured and expanded.
Cell culture
Murine BM-MSCs were cultured in DMEM supplemented with 10%
FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, and 100 U/ml P/S
◀ Figure 5. Body weight, cortical bone, trabecular bone, and glucose/triglycerides of BYL719 treated mouse.A Body weight of mice from P8 (start of treatment with DMSO or BYL719) to P30 (experimental endpoint). Data shown as mean  SEM (n per group detailed in
Fig 3). #P < 0.05, ** or ##P < 0.01, *** or ###P < 0.001; two-way ANOVA. Asterisks refer to significance between Acvr1Q207D groups (treated daily with BYL719)
compared to Acvr1Q207D treated with DMSO. Similarly, # refers to significance between groups treated daily with BYL719, compared to control group treated with
DMSO.
B, C Femur length, cortical bone, and trabecular bone parameters of different mice groups at P30. Asterisks refer to significance between Acvr1Q207D groups (treated
with daily or intermittent BYL719) compared to Acvr1Q207D treated with DMSO and between control groups (treated with daily or intermittent BYL719) compared to
control group treated with DMSO. Data shown as mean  SEM (n per group detailed in Fig 3). **P < 0.01, ***P < 0.001; two-way ANOVA.
D Glucose and triglyceride levels at P30 of mice fed ad libitum. Data shown as box and whisker plot. Median is plotted, and box extends from 25th to 75th percentiles.
Whiskers go from Min to Max. One-way ANOVA.
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(Biological Industries) and incubated at 37°C with 5% CO2. For
osteogenic differentiation, cells were cultured in a-MEM with 10%
FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 50 lM ascorbic
acid, 10 mM b-glycerophosphate, and 100 U/ml P/S (Biological
Industries) for 14 days.
Unless otherwise stated, 10 lM A66 (Selleckchem) or 10 lM
BYL719 (Chemietek) was used for 16 h, in the absence of
FBS, prior to cell harvest. 2 nM BMP2, 2 nM BMP6, and 2 nM
activin A (R&D) were used for 2 h (qRT–PCRs) or 1 h (Western
blot).
Retroviral transduction
Bone marrow mesenchymal stem cells from control mice were
infected with mock virus (pMSCV-GFP) or with viruses expressing
wild-type Acvr1 (WT), Acvr1Q207D (QD), or Acvr1R206H (RH). Plas-
mids with WT, QD, and RH Acvr1 forms were kindly provided by
Dr. Petra Seemann and were subcloned into pMSCV viral vector.
Acvr1 expression levels were analyzed by qRT–PCR and Western
blot.
Western blot
Cell lysates were resolved on PAGE and transferred to Immobilon-P
membranes (Millipore). Primary antibodies against SMAD1 (Cell
Signaling, 6944), p-SMAD1/5 (Cell Signaling, 9516), p-GSK3 (Cell
Signaling, 9331), p-P38 (Cell Signaling, 9211), p-S6 (Cell Signaling,
2211), HA (Roche, 11666606001), and a-TUBULIN (Calbiochem,
CP06) were used at 1:1,000 dilution. Antibody against b-ACTIN
(Abcam, Ab6276) was used at 1:4,000 dilution. Antibody against
ID1 (Santa Cruz Biotechnology, C-20) was used at 1:200 dilution.
Binding was detected with horseradish peroxidase-conjugated
secondary antibodies (Sigma). Immunoblot images were obtained
with Fujifilm LAS3000.
Gene expression analysis
Total RNA was extracted from BM-MSCs using TRIsure reagent
(Bioline). At least 2 lg of purified RNA was reverse-transcribed
using the High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). Quantitative PCRs were carried out on ABI Prism 7900
HT Fast Real-Time PCR System with TaqMan 50-nuclease probe
method (Applied Biosystems) and SensiFAST Probe Hi-ROX Mix
(Bioline). All transcripts were normalized using Tbp as an endoge-
nous control (Appendix Table S1).
Heterotopic ossification mouse model
To study heterotopic ossification in vivo, we used Cre-inducible
constitutively active ACVR1Q207D (CAG-Z-EGFP-caALK2) mouse
model as previously described (Fukuda et al, 2006; Yu et al, 2008;
Shimono et al, 2011). We analyzed mice of both genders with a
C57BL/6 background. In order to induce heterotopic ossification in
P7 ACVR1Q207D mice, 1 × 108 pfu of adenovirus-Cre (Ad-CMV-Cre,
Viral Vector Production Unit, UAB) and 0.3 lg of cardiotoxin
(L8102, Latoxan) in 10 ll 0.9% NaCl volume were injected into the
left hindlimb. Control groups had the same procedure without
Ad-Cre in the injection. On P8, mice started receiving either placebo
(intraperitoneal administration (i.p.) of DMSO) or BYL719 (i.p. of
25 mg/kg), both diluted in 0.5% carboxymethylcellulose sodium
(Sigma). Treatment groups received BYL719 either daily or with
intermittent administration (see Fig 4A). Mice were housed under
controlled conditions (12-h light/12-h dark cycle, 21°C, 55% humid-
ity) and fed ad libitum with water and a 14% protein diet (2014
Teklad, Envigo). Mice were regularly weighed over the whole
period. For in vivo studies, experimental endpoint was determined
to be at P30, when most of the untreated mice had presented hetero-
topic ossification. Primers used to detect mice genotype were 50-G
TGCTGGTTATTGTGCTGTCTC-30 and 50-GACGACAGTATCGGCCTC
AGGAA-30. All procedures were approved by the Ethics Committee
for Animal Experimentation of the Generalitat de Catalunya.
Micro-computed tomography analysis
Caudal half of mice were collected and fixed in 4% paraformalde-
hyde (PFA) for 48 h at 4°C. Specimens were conserved in PBS
and high-resolution images were acquired using a computerized
microtomography imaging system (SkyScan 1076, Bruker
microCT), in accordance with the recommendations of the Ameri-
can Society of Bone and Mineral Research (ASBMR). Samples
were scanned in air at 50 kV and 200 lA with an exposure time
of 800ms, using a 1-mm aluminum filter and an isotropic voxel
size of 9 lm. Two-dimensional images were acquired every 1° for
180° rotation and subsequently reconstructed, analyzed for bone
parameters, and visualized by NRecon v1.6, CT-Analyser v1.13,
and CTVox v3.3 programs (Bruker), respectively. For heterotopic
ossification, manual VOIs comprising heterotopic ossifications
were employed and a binary threshold was established at 25–255.
For trabecular and cortical evaluation, non-injected hindlimbs
were collected and femurs were analyzed with the parameters
detailed above. For trabecular measurements, manual VOIs start-
ing 100 slices from distal growth plate of the femur and extending
to the diaphysis for 150 slices were employed and a binary
threshold was established at 20–255. For cortical measurements,
manual VOIs of 100 slices delineating the femur medial cortex
around the femoral midshaft were employed and a binary thresh-
old was established at 50–255.
Histology
Whole legs were fixed in 4% PFA for 48 h at 4°C, decalcified in
16% EDTA pH 7.4 for 6 weeks, and embedded in paraffin. 5-lm
sections were cut and stained with hematoxylin and eosin, fast
green/safranin O, or Masson’s trichrome (PanReac AppliChem). For
whole leg visualization, images were obtained with Brightfield
SteREO Lumar v.12 stereomicroscope (Carl Zeiss). For higher
magnifications, images were obtained with Brightfield Eclipse E800
(Nikon).
Blood tests
Blood samples were collected by cardiac puncture at sacrifice, and
centrifuged at 1,850 × g for 15 min at 4°C to obtain serum samples.
Aliquots were analyzed at Clinical Biochemistry Service of
the Faculty of Veterinary Medicine (Universitat Auto`noma de
Barcelona).
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Statistical analysis
The results were expressed as mean  SEM. Unless stated other-
wise in each figure legend, statistical analysis was performed using
ANOVA. Detailed P-values are provided in Appendix Table S2.
Unless stated otherwise in each figure legend, results were repli-
cated four times with technical triplicates. Heterotopic ossification
induction was performed blinded to mouse and group identity. The
evaluation of heterotopic ossification formation and quantification
was performed independently and blinded to mouse and treatment
group. Statistical tests were performed on GraphPad Prism 6
(GraphPad Software Inc.).
Expanded View for this article is available online.
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